

Christoph Rader

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2373131/christoph-rader-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

4,858
citations

37
h-index

67
g-index

121
ext. papers

5,919
ext. citations

6.7
avg, IF

5.9
L-index

#	Paper	IF	Citations
116	ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2022 , 118, 106872-7		
115	Defining the Biochemical Role of Sialic Acid-Binding Immunoglobulin-like Lectin-6 in Adhesion and Migration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021 , 138, 2623-2623	2.2	
114	Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. <i>Molecular Therapy - Oncolytics</i> , 2021 , 20, 387-398	6.4	5
113	Discovery of ammosesters by mining the <i>Streptomyces uncialis</i> DCA2648 genome revealing new insight into ammosamide biosynthesis. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2021 , 48,	4.2	4
112	An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. <i>Biochemistry</i> , 2021 , 60, 1080-1087	3.2	1
111	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021 , 17, e1009501	7.6	20
110	Antibody-based cancer therapy. <i>Oncogene</i> , 2021 , 40, 3655-3664	9.2	11
109	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. <i>Blood</i> , 2021 , 138, 1843-1854	2.2	3
108	Challenges and Opportunities to Develop Eneidiyne Natural Products as Payloads for Antibody-Drug Conjugates. <i>Antibody Therapeutics</i> , 2021 , 4, 1-15	5.8	11
107	Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 2581-2591	10.7	4
106	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. <i>Cancer Cell</i> , 2021 , 39, 193-208.e10	24.3	50
105	A new immunochemical strategy for triple-negative breast cancer therapy. <i>Scientific Reports</i> , 2021 , 11, 14875	4.9	2
104	The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. <i>Blood Advances</i> , 2021 , 5, 3152-3162	7.8	2
103	Redirecting cytotoxic T cells with chemically programmed antibodies. <i>Bioorganic and Medicinal Chemistry</i> , 2020 , 28, 115834	3.4	1
102	Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format. <i>Biomolecules</i> , 2020 , 10,	5.9	4
101	Chemically Programmable and Switchable CAR-T Therapy. <i>Angewandte Chemie</i> , 2020 , 132, 12276-12283	3.6	1
100	Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications. <i>Journal of Biological Chemistry</i> , 2020 , 295, 5995-6006	5.4	14

99	Generation and validation of structurally defined antibody-siRNA conjugates. <i>Nucleic Acids Research</i> , 2020 , 48, 5281-5293	20.1	18
98	Chemically Programmable and Switchable CAR-T Therapy. <i>Angewandte Chemie - International Edition</i> , 2020 , 59, 12178-12185	16.4	11
97	Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 2020 ,		16
96	Bispecific antibodies in cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020 , 65, 9-16	11.4	32
95	Characterization of TnmH as an -Methyltransferase Revealing Insights into Tiancimycin Biosynthesis and Enabling a Biocatalytic Strategy To Prepare Antibody-Tiancimycin Conjugates. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 8432-8441	8.3	7
94	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. <i>Nature Communications</i> , 2020 , 11, 6013	17.4	45 ⁰
93	Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. <i>Frontiers in Immunology</i> , 2019 , 10, 1994	8.4	6
92	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. <i>Blood</i> , 2019 , 134, 432-444	2.2	17
91	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. <i>Cancer Cell</i> , 2019 , 35, 489-503.e8	24.3	123
90	An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. <i>Methods</i> , 2019 , 154, 70-76	4.6	6
89	Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues. <i>Cell Chemical Biology</i> , 2019 , 26, 1229-1239.e9	8.2	13
88	Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. <i>Bioconjugate Chemistry</i> , 2019 , 30, 2889-2896	6.3	16
87	Dual-mechanistic antibody-drug conjugate site-specific selenocysteine/cysteine conjugation. <i>Antibody Therapeutics</i> , 2019 , 2, 71-78	5.8	19
86	A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib. <i>Blood</i> , 2019 , 134, 2861-2861	2.2	0
85	Engineering Dual Variable Domains for the Generation of Site-Specific Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2019 , 2033, 39-52	1.4	5
84	Chimeric Antigen Receptor Library Screening Using a Novel NF- κ B/NFAT Reporter Cell Platform. <i>Molecular Therapy</i> , 2019 , 27, 287-299	11.7	21
83	Rabbit models of human diseases for diagnostics and therapeutics development. <i>Developmental and Comparative Immunology</i> , 2019 , 92, 99-104	3.2	12
82	Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies. <i>Cancer Immunology Research</i> , 2018 , 6, 1008-1013	12.5	5

81	CAR T cells targeting Integrin are effective against advanced cancer in preclinical models. <i>Advances in Cell and Gene Therapy</i> , 2018 , 1, e11	1.2	28
80	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018 , 132, 521-532	2.2	56
79	A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries. <i>Journal of Molecular Biology</i> , 2018 , 430, 4387-4400	6.5	1
78	Comparative Studies of the Biosynthetic Gene Clusters for Anthraquinone-Fused Eneidyne Shedding Light into the Tailoring Steps of Tiamcymycin Biosynthesis. <i>Organic Letters</i> , 2018 , 20, 5918-5921	6.2	22
77	Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5467-E5476	11.5	37
76	Chemical Assembly of Antibody-Drug Conjugates. <i>Milestones in Drug Therapy</i> , 2017 , 1-28		
75	From rabbit antibody repertoires to rabbit monoclonal antibodies. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e305	12.8	69
74	Stable and Potent Selenomab-Drug Conjugates. <i>Cell Chemical Biology</i> , 2017 , 24, 433-442.e6	8.2	20
73	Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. <i>Nature Communications</i> , 2017 , 8, 1112	17.4	52
72	Genome Mining of <i>Micromonospora yangpuensis</i> DSM 45577 as a Producer of an Anthraquinone-Fused Eneidyne. <i>Organic Letters</i> , 2017 , 19, 6192-6195	6.2	37
71	Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy. <i>Journal of Biological Chemistry</i> , 2017 , 292, 16760-16772	5.4	4
70	Mining Native Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. <i>Journal of Molecular Biology</i> , 2017 , 429, 2954-2973	6.5	29
69	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. <i>European Polymer Journal</i> , 2017 , 88, 524-552	5.2	93
68	Utilization of Selenocysteine for Site-Specific Antibody Conjugation. <i>Methods in Molecular Biology</i> , 2017 , 1575, 145-164	1.4	5
67	Chemically Programmed Bispecific Antibodies in Diabody Format. <i>Journal of Biological Chemistry</i> , 2016 , 291, 19661-73	5.4	26
66	Engineered production of cancer targeting peptide (CTP)-containing C-1027 in <i>Streptomyces globosporus</i> and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 3887-3892	3.4	6
65	Strain Prioritization and Genome Mining for Eneidyne Natural Products. <i>MBio</i> , 2016 , 7,	7.8	66
64	Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates. <i>Journal of Biological Chemistry</i> , 2016 , 291, 7558-70	5.4	11

63	Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts. <i>Organic and Biomolecular Chemistry</i> , 2016 , 14, 5141-7	3.9	18
62	Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2271-2275	6.3	14
61	Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. <i>Bioconjugate Chemistry</i> , 2015 , 26, 2243-8	6.3	37
60	Lipid-directed vinculin dimerization. <i>Biochemistry</i> , 2015 , 54, 2758-68	3.2	13
59	The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. <i>Cancer Immunology Research</i> , 2015 , 3, 125-35	12.5	294
58	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. <i>Experimental Hematology</i> , 2015 , 43, 770-4.e2	3.1	15
57	Chemical biology: How to minimize antibodies. <i>Nature</i> , 2015 , 518, 38-9	50.4	14
56	Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. <i>Cancer Immunology Research</i> , 2015 , 3, 206-16	12.5	112
55	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. <i>PLoS ONE</i> , 2015 , 10, e0133152	3.7	56
54	Antibody conjugation via one and two C-terminal selenocysteines. <i>Methods</i> , 2014 , 65, 133-8	4.6	34
53	Chemically programmed antibodies. <i>Trends in Biotechnology</i> , 2014 , 32, 186-97	15.1	36
52	Carlos F. Barbas III (1964-2014): Visionary at the interface of chemistry and biology. <i>ACS Chemical Biology</i> , 2014 , 9, 1645-6	4.9	
51	Improving the serum stability of site-specific antibody conjugates with sulfone linkers. <i>Bioconjugate Chemistry</i> , 2014 , 25, 1402-7	6.3	70
50	Selection of apoptotic cell specific human antibodies from adult bone marrow. <i>PLoS ONE</i> , 2014 , 9, e95999	3.7	2
49	Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates. <i>Chemistry and Biology</i> , 2014 , 21, 1670-9		19
48	Harnessing the FcγR receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2014 , 74, 7510-7520	10.1	11
47	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. <i>Clinical Cancer Research</i> , 2013 , 19, 3153-64	12.9	330
46	Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 4168-4168	2.2	1

45	Chemically programmed bispecific antibodies that recruit and activate T cells. <i>Journal of Biological Chemistry</i> , 2012 , 287, 28206-14	5.4	22
44	Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format. <i>Methods in Molecular Biology</i> , 2012 , 901, 209-32	1.4	7
43	Selection of human Fab libraries by phage display. <i>Methods in Molecular Biology</i> , 2012 , 901, 81-99	1.4	2
42	Generation of human Fab libraries for phage display. <i>Methods in Molecular Biology</i> , 2012 , 901, 53-79	1.4	6
41	Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates. <i>Bioconjugate Chemistry</i> , 2012 , 23, 2007-13	6.3	31
40	Targeting malignant B cells with an immunotoxin against ROR1. <i>MAbs</i> , 2012 , 4, 349-61	6.6	50
39	Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. <i>PLoS ONE</i> , 2012 , 7, e52655	3.7	36
38	Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012 , 120, 1349-1349	2.2	
37	Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. <i>PLoS ONE</i> , 2011 , 6, e21018	3.7	63
36	DARTs take aim at BITEs. <i>Blood</i> , 2011 , 117, 4403-4	2.2	56
35	Monoclonal Antibody Therapy for Cancer 2011 , 59-83		
34	Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution for multimeric binding to the Rev response element. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 5810-4	11.5	106
33	Mining human antibody repertoires. <i>MAbs</i> , 2010 , 2, 365-78	6.6	40
32	Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. <i>Journal of Molecular Biology</i> , 2010 , 397, 697-708	6.5	24
31	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. <i>Blood</i> , 2010 , 116, 4532-41	2.2	200
30	Molecularly defined antibody conjugation through a selenocysteine interface. <i>Biochemistry</i> , 2009 , 48, 12047-57	3.2	86
29	Overview on concepts and applications of Fab antibody fragments. <i>Current Protocols in Protein Science</i> , 2009 , Chapter 6, Unit 6.9	3.1	18
28	E. coli expression and purification of Fab antibody fragments. <i>Current Protocols in Protein Science</i> , 2009 , Chapter 6, Unit 6.10	3.1	19

27	A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. <i>Blood</i> , 2009 , 114, 4494-502	2.2	18
26	Generation and selection of rabbit antibody libraries by phage display. <i>Methods in Molecular Biology</i> , 2009 , 525, 101-28, xiv	1.4	22
25	Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. <i>Journal of Molecular Biology</i> , 2008 , 384, 1143-56	6.5	24
24	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. <i>Clinical Cancer Research</i> , 2008 , 14, 396-404	12.9	173
23	An engineered selenocysteine defines a unique class of antibody derivatives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 12451-6	11.5	68
22	Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 5785-8	2.9	9
21	Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. <i>Journal of Immunological Methods</i> , 2007 , 318, 75-87	2.5	30
20	Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.. <i>Blood</i> , 2007 , 110, 167-167	2.2	0
19	Monoclonal Antibodies in Cancer Therapy 2007 , 453-484		1
18	Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. <i>International Journal of Cancer</i> , 2006 , 119, 1194-207	7.5	39
17	Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8293-8	11.5	75
16	The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. <i>Journal of Neuroscience</i> , 2005 , 25, 808-22	6.6	188
15	Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. <i>Cancer Research</i> , 2005 , 65, 972-81	10.1	51
14	Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. <i>Journal of Immunological Methods</i> , 2004 , 288, 149-64	2.5	36
13	Isolation of human prostate cancer cell reactive antibodies using phage display technology. <i>Journal of Immunological Methods</i> , 2004 , 291, 137-51	2.5	43
12	Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5630-40	8.3	38
11	Simultaneous Silencing of Two Independent Signaling Pathways Essential for Angiogenesis Using Bispecific, Tetravalent Intra-Diabodies.. <i>Blood</i> , 2004 , 104, 5284-5284	2.2	
10	Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 5396-400	11.5	79

9	Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. <i>Journal of Biological Chemistry</i> , 2003 , 278, 47812-9	5.4	43
8	Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. <i>Journal of Molecular Biology</i> , 2003 , 325, 325-35	6.5	87
7	A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. <i>Journal of Molecular Biology</i> , 2003 , 332, 889-99	6.5	71
6	Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. <i>FASEB Journal</i> , 2002 , 16, 2000-2	0.9	62
5	Antibody libraries in drug and target discovery. <i>Drug Discovery Today</i> , 2001 , 6, 36-43	8.8	30
4	Catalytic antibodies as magic bullets. <i>Chemistry - A European Journal</i> , 2000 , 6, 2091-5	4.8	21
3	The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. <i>Journal of Biological Chemistry</i> , 2000 , 275, 13668-76	5.4	88
2	Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. <i>Journal of Biological Chemistry</i> , 2000 , 275, 36073-8	5.4	51
1	Phage display of combinatorial antibody libraries. <i>Current Opinion in Biotechnology</i> , 1997 , 8, 503-8	11.4	191